In separate pretrial orders, the courts overseeing federal multidistrict litigation for Invokana and for Atrium C-Qur both ruled that plaintiffs may file their claims directly in the proceedings.
Direct filing eliminates delays involved in the transfer or removal of cases from other federal district courts.
- 126 cases have been filed in MDL 2750, IN RE: Invokana (Canagliflozin) Products Liability Litigation, before US District Judge Brian R. Martinotti in the District of New Jersey.
- 24 cases have been filed MDL 2753, IN RE: Atrium Medical Corp. C-Qur Mesh Products Liability Litigation, before US District Judge Landya B. McCafferty in the District of New Hampshire.
The US Judicial Panel on Multidistrict Litigation (JPMDL) created the Invokana MDL on December 12, 2016. Plaintiffs charge that taking Invokana or Invokamet may result in patients suffering various injuries, including diabetic ketoacidosis and kidney damage. The actions thus implicate many common issues about the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs.
Direct filing does not stop the running of any statute of limitation or determine the choice of law. It does not constitute a waiver of Lexecon v. Milberg Weiss, 523 U.S. 26 (1998), which holds that MDL transferee judges lack authority to try cases that originated outside of the transferee court. Upon completion of pretrial proceedings to a directly-filed case, the court will transfer that case to the district court based on the district designated in the complaint.
Any attorney in good standing in any federal court is admitted pro hac vice in the litigation.
Atrium C-Qur mesh MDL
The JPMDL created the Atrium Medical Corp. C-Qur Mesh Products Liability MDL on December 8, 2016. The plaintiffs allege that defects in defendants’ C-Qur mesh products incite an allergic or inflammatory response that causes severe complications. All the actions involve factual questions about whether C-Qur mesh was defectively designed or manufactured, whether defendants knew or should have known of the alleged propensity of C-Qur mesh to result in an allergic or inflammatory response, and whether defendants provided adequate instructions and warnings with the mesh.
Direct filing does not constitute a determination that venue is proper, has no impact on the choice of law including the statute of limitation.
Atrium is one of many hermia patch manufacturers facing lawsuits over making defective products. More hernia mesh MDLs may be created – See MDL Motion Expected in Ethicon Physiomesh Hernia Repair Product Litigation.